Mood Disorders Mental Problems Related to Mood Mood episodes Mood Disorders Specifiers Mood Sustained emotion that colors the way we view life. Mood D/O’s seen in 20% of women and 10% of men* 50% of typical mental health practice Male Risk Factors Isolation Anhedonia Limited Physical Activity Limited Self-reflection Denial/Pessimistic Mood Disorders Major Depressive Episode Dysthymic Depressive Disorder NOS Manic Episode Bipolar I Bipolar II Cyclothymic Bipolar Disorder NOS Other Mood Disorders Mood Disorder due to GMC? Substance-Induced Mood Disorder Mood Disorder NOS Other causes of Depressive and Manic Symptoms Schizoaffective Disorder Cognitive Disorders with depressed mood Adjustment Disorder with Depressed Mood Personality Disorders Bereavement Specifiers With Atypical Features* With Melancholic Features With Catatonic Features With Postpartum Onset Course of Recurrent Episodes With/without Full Interepisode Recovery With Rapid Cycling With Seasonal Pattern Major Depressive Episode Quality of depressed mood Duration Symptoms Impairments Exclusions Depressive Symptoms Depressed mood Anhedonia Lost appetite and weight Insomnia Psychomotor retardation Agitation Suicidal ideation Theories of Depression Cognitive (Beck) Learning (Seligman) Neuroendocrine Circadian Rhythm Hypotheses Neurotransmitter Cognitive Aspects of Depression Pessimism (underestimates likelihood of success) Lack of Self-esteem (underestimate the value of past achievements) “It doesn’t matter” (responses won’t make a difference) Biased judgement (toward negativism) Neuroendocrine Abnormalities Hypercorticolism (dysfunction in HAP axis) Dexamethasone suppression test – – – – basis of test-diagnostic and treatment marker procedure Problems Utility? Blunting of plasma growth hormone Blunting of serotonin-mediated increase in plasma prolactin Circadian Rhythm Abnormalities Patterns of insomnia and hypersomnia Diurnal fluctuations in mood Seasonal pattern depression (ultradian) Abnormalities in sleep architecture Impact of: – antidepressants on sleep architecture – phototherapy – reset biological clocks (endogenous zeitgebers) Medication: Placebo? Kirsh et al (1999) 80 % Placebo Saperstein (1996) 50% Placebo Leuchter et al (2002) changes in brain activation APA (1998) Equal to Psychotherapy – More cost effective – Less side effects Prescription privledges? – http://www.apa.org/apags/profdev/prespriv.html Pharmalogical Treatments “Trials” Tricyclic antidepressants ($15/month) – Imipramine, Noratriptyline, Desipramine & Amitriptyline MAO Inhibitors*- ($15/month) – Nardil, Parnate & Marplan: 4-5 week build-up Heterocyclic antidepressants ($50-120/month) – 4 to 8 weeks to produce effect – SSRI’s (Prozac, Zoloft, Celexa) – Dopamine specific reuptake inhibitors (Wellbutrin) Lithium (for Bipolar D/O) Response to Pharmacological Treatment Typical 3 part response – Sleep improves – Energy increases – Mood improves Suicide potential greatest after energy increases, but before mood improves Who Rx’s most antidepressants? – Problems? Consider side effect profile Predictors of Response to Antidepressant Medication Positive – – – – Gradual onset Anorexia with weight loss Middle, Late Insomnia Psychomotor retardation Negative – Multiple prior episodes – Delusions & more “complicated” problems Outcome of Antidepressant Treatment Average duration of MDD= 6 months 66% with MDD recover within 1 year and 80% recover within 2 years Among recovered patients, 33% will relapse in 1 year; 75% will relapse in 5 years Double depression (MDD + Dysthymia) doubles relapse rate Only 15% of hospitalized will not relapse Critical Treatment Components Psychoeducation – Ex. Abrupt stopping can cause severe side effects and intensify the depressive symptoms. Increased structure Decreased stress Rapport and instillation of hope Psychotherapy and pharmacotherapy is most effective, especially for severe levels of depression – 80% of pts. receiving some combination of therapy and medication made significant improvements (Little, et al, 1999 AJP: 155) Tricyclic Antidepressants MOA: inhibit the NE reuptake Try for 6 months then taper if Sx. abate MUST monitor – – – – mood weight BP changes (usually lower) compliance Trycyclic Side Effects Muscarinic receptor blockade (anticholinergic) – dry mouth, constipation, sedation, fatigue – Loss of libido and/or sexual dysfunction – Imipramine, Nortriptyline and Desipramine Histimic receptor blockade – sedation and weight gain Alpha-adrenergic receptor blockade – Postural hypotension – Confusion and delirium in the elderly Sx. of TCA withdrawal Loose stools Urinary frequency Headache Hypersalivation SSRIs Becoming most widely prescribed antidepressants Relatively benign side effect profile Examples: Prozac (Fluoxetine) and Zoloft (Sertraline); Lexapro (Escitalopram) Very popular in primary care Also used with OCD and Anxiety D/Os Dopamine Dysfunctional mesolimbic pathway & hypoactive D1 receptors Associated with lower levels in depression and higher levels in mania Ldopa (PD) leads to depression Tyrosine, Amphetamine & Wellbutrin reduce Dep. Sx. and increase Dopamine Prozac Advantages – Most limited and transient side effect profile – little sedation, weight gain and hypotension – minimal overdose risk Disadvantages – long half life, psychotic Sx.-drug interactions, child/adolescent contraindications and expensive $ (110/month) Prozac continued Drug-Drug Interactions – Increases plasma levels of TCA’s and neuroleptics – Hypermetabolic syndrome with MAOI’s Side Effects – GI, anxiety, insomnia, headaches, tremor, agitation, insomnia, anorexia, loss of libido and or sexual dysfuntion – Least likely to cause sedation Symptoms of Serotonin Withdrawal Flu-like (fatigue, nausea, loose stools) Lightheadedness/dizziness Uneasiness/restlessness Sleep and sensory disturbances Headache Dx. Confirmed when Sx. remit after restarting SSRI (usually 12-24 hours) Electroconvulsive Therapy Controversies Progress Side effects Efficacy Women & Depression Women 2x likely to be diagnosed, especially younger women Depression is misdiagnosed 30 to 50 % of the time 70% of Rx’s given to women, often without proper monitoring Higher rates of physical and sexual abuse Needs – More Prevention – More Research of barriers to treatment – More research on differential risk Depression and African Americans Higher risk due to SES Misdiagnosis – – – – Mistrust of medical system Cultural barriers Primary reliance on family and church “Masked” by medical conditions, somatic complaints or substance abuse – SES limiting access to medical care African American Attitudes toward depression (National Mental Health Association, 1996) 63% (vs. 54%) “depression is a personal weakness” Only 31% believed depression is a health problem Only 20% said they would seek treatment Only 25% connected change in eating habits or sleep with depression; 16% irritability Only 33% said they would take medication for depression (vs. 69% of general population) 67% believed prayer & faith alone would successfully treat depression “almost all of the time or some of the time.” Depression and the Elderly Depression is NOT a normal part of aging, although 58% of elders believe this 6 million affected, most women, < 10% tx’d 15% in community vs. 25% in ECFs Often misinterpreted as medical condition Elders with comorbid depression have 50% higher health care costs; Depression is often secondary 40% experience reoccurrence Only 38% believe it is a “health problem” Only 42% would seek professional help ECT efficacious Polypharmacy & Undermedication Suicide & the Elderly Most at risk, 50% higher; 2/3 are due to untreated depression 20-25% of all suicides occur in the elderly EA men over 80 are 6x more likely Many have recently visited their PCP – 20% the same day – 40% within one week – 70% within one month • • • • • • Suicide Incidence History Age/Gender/Race? Marital Status Life Stress Psychiatric Disorders • Parasuicidal behaviors • Children & Adolescents • Assessment & Prevention • Contracts----Baker Act